Safety and Efficacy Study of GCSF Therapy to Treat Patients at High Risk for Chemotherapy Induced Severe Neutropenia
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
The overall purpose of this study is to assess the dose response, efficacy, and safety of
three different dose levels of AVI 014 (granulocyte colony-stimulating factor [G-CSF]) in
breast cancer patients at high (>20%) risk for chemotherapy-induced severe neutropenia.